Daniel Wagner

Daniel (Dan) Wagner is a medical device and biotechnology executive who leads Otolith Labs, the Washington, DC company building the OtoBand, a non-invasive wearable that uses patented non-invasive Vestibular Resonance Therapy (nVRT) to address chronic vertigo. With more than two decades of commercial experience spanning 60-plus countries and roles at Spark Biomedical, Olympus Corporation, HeartSciences and Signature Biologics, Wagner advised Otolith for over five years before joining full-time as Chief Commercial Officer in 2024 and now serves as Chief Executive Officer, steering the company's go-to-market strategy toward a planned market launch.